

--- -----
? s jurkat

S1 33 JURKAT
? s leukemia

S2 1672 LEUKEMIA
? s s1 and s2

33 S1
1672 S2
S3 9 S1 AND S2
? rd

>>>Duplicate detection is not supported for File 340.
>>>All specified files are unsupported, command ignored.
? t s3/3,k,ab/1-9

3/3,K,AB/1
DIALOG(R) File 340:CLAIMS(R)/US PATENT
(c) 2000 IFI/CLAIMS(r). All rts. reserv.

Dialog Acc No: 3372380 IFI Acc No: 0026666
Document Type: C
DETECTION AND MODULATION OF IAPS FOR THE DIAGNOSIS AND TREATMENT OF
PROLIFERATIVE DISEASE; DETECTING MODULATORS OF INHIBITOR OF APOPTOSIS;
INCUBATING CELL THAT EXPRESSES INHIBITOR OF APOPTOSIS WITH MODULATOR,
MONITOR THE EXPRESSION OF INHIBITOR OF APOPTOSIS, INCREASE IN APOPTOSIS IS
INDICATOR OF THE PRESENCE OF A MODULATOR
Inventors: Baird Stephen (CA); Korneluk Robert G (CA); Liston Peter (CA);
MacKenzie Alexander E (CA); Pratt Christine (CA); Tsang Benjamin K (CA)
Assignee: Apoptogen Inc CA Assignee Code: 54252
Patent (No,Date), Applic (No,Date)
US 6107041 20000822 US 98212971 19981216
Calculated Expiration: 20170213
Division Pat (No), Applic (No,Date): US 97800929
19970213
Priority Applic (No,Date): US 98212971 19981216; US 97800929 19970213
Provisional Applic (No,Date): US 60-17354 19960426; US 60-30590 19961114

Abstract:

Disclosed are diagnostic and prognostic kits for the detection and
treatment of proliferative diseases such as ovarian cancer, breast cancer,
and lymphoma. Also disclosed are cancer therapeutics utilizing IAP
antisense nucleic acids IAP fragments, and antibodies which specifically
bind IAP polypeptides.

Non-exemplary Claims:

...of claim 15, wherein said cancer cell line is a HeLa cell line, a
myelogenous leukemia cell line, a colorectal adenocarcinoma cell
line, a Burkitt's lymphoma cell line, a promyelocytic leukemia
cell line, or a melanoma cell line...

...line is a T-cell line, such as H9, CEM/CM-3, 6T-CEM, or Jurkat
cell lines...

...of an ovarian cancer cell, breast cancer cell, pancreatic cancer cell,

lymphoma cell, melanoma cell, leukemia cell, and lung cancer cell

...

3/3,K,AB/2

DIALOG(R) File 340:CLAIMS(R)/US PATENT

(c) 2000 IFI/CLAIMS(r). All rts. reserv.

Dialog Acc No: 3346817 IFI Acc No: 0020303

Document Type: C

TRANSFECTED HUMAN CELLS EXPRESSING HUMAN ALPHA-GALACTOSIDASE A PROTEIN;
NUCLEOTIDE SEQUENCES CODING A MAMMALIAN ENZYMATIC POLYPEPTIDE; FOR GENE
THERAPY OF LYSOSOMAL STORAGE DEFECT

Inventors: Borowski Marianne (US); Gillispie Frances P (US); Kinoshita
Carol M (US); Selden Richard F (US); Treco Douglas A (US); Williams
Melanie D (US)

Assignee: Transkaryotic Therapies Inc Assignee Code: 40420

Patent (No,Date), Applic (No,Date)

US 6083725 20000704 US 97928881 19970912

Priority Applic(No,Date): US 97928881 19970912

Provisional Applic(No,Date): US 60-26041 19960913

Abstract:

A therapeutic method whereby an individual suspected of having an alpha-galactosidase A deficiency, such as Fabry disease, is treated either with (1) human cells that have been genetically modified to overexpress and secrete human alpha-gal A, or (2) purified human alpha-gal A obtained from cultured, genetically modified human cells.

Non-exemplary Claims:

...group consisting of Bowes melanoma cells, Daudi cells, HeLa cells, HL-60 cells, HT1080 cells, Jurkat cells, KB carcinoma cells, K-562 leukemia cells, MCF-7 breast cancer cells, MOLT-4 cells, Namalwa cells, Raji cells, RPMI 8226...24. The clonal cell line of claim 12, wherein said cells are K-562 leukemia cells...

3/3,K,AB/3

DIALOG(R) File 340:CLAIMS(R)/US PATENT

(c) 2000 IFI/CLAIMS(r). All rts. reserv.

Dialog Acc No: 3231884 IFI Acc No: 9938263

Document Type: C

ANTIBODIES TO LEUKEMIA INHIBITORY FACTOR; A MONOCLONAL ANTIBODY
THERAPEUTIC AGENTS THAT SPECIFICALLY BINDS HUMAN LEUKEMIA INHIBITORY
FACTOR AND NEUTRALIZES A BIOLOGICAL ACTIVITY OF HUMAN LEUKEMIA
INHIBITORY

Inventors: Kim Kyung Jin (US)

Assignee: Genentech Inc Assignee Code: 07579

Patent (No,Date), Applic (No,Date)

US 5980894 19991109 US 97833854 19970410

Calculated Expiration: 20120508

Continuation Pat(No),Applic(No,Date): ABANDONED

US 92880400

19920508; ABANDONED

US 9356966

19930429; US 5668003

US 95438455

19950510

Division Pat(No),Applic(No,Date): US 5688681

US 94258918

19940613

Priority Applic(No,Date): US 97833854

19970410; US 92880400

19920508;

US 9356966

19930429; US 95438455

19950510; US 94258918

19940613

Abstract:

The invention relates to monoclonal antibodies to human leukemia inhibitory factor. The disclosed monoclonal antibodies are believed to recognize unique epitopes on hLIF and are useful in the treatment of conditions wherein the presence of hLIF causes or contributes to undesirable pathological effects, such as cachexia, dysregulated calcium

metabolism, or excessive bone cell proliferation, and in the detection of hLIF, for example, in clinical samples or specimens.

ANTIBODIES TO **LEUKEMIA** INHIBITORY FACTOR...

...A MONOCLONAL ANTIBODY THERAPEUTIC AGENTS THAT SPECIFICALLY BINDS HUMAN **LEUKEMIA** INHIBITORY FACTOR AND NEUTRALIZES A BIOLOGICAL ACTIVITY OF HUMAN **LEUKEMIA** INHIBITORY

Abstract:

The invention relates to monoclonal antibodies to human **leukemia** inhibitory factor. The disclosed monoclonal antibodies are believed to recognize unique epitopes on hLIF and...

Exemplary Claim:

...W I N G

1. A composition comprising: a monoclonal antibody that specifically binds human **Leukemia** Inhibitory Factor and neutralizes a biological activity of human **Leukemia** Inhibitory Factor; and a pharmaceutically acceptable carrier.

Non-exemplary Claims:

...to claim 1, wherein the monoclonal antibody is competitively inhibited in its binding to human **Leukemia** Inhibitory Factor by a monoclonal antibody selected from the group consisting of monoclonal antibodies produced...

...to claim 1, wherein the monoclonal antibody is capable of reducing the ability of human **Leukemia** Inhibitory Factor to inhibit growth of M1-T22 murine myeloid leukemic cells, wherein the monoclonal antibody is competitively inhibited in its binding to human **Leukemia** Inhibitory Factor by a monoclonal antibody selected from the group consisting of monoclonal antibodies produced...

...to claim 1, wherein the monoclonal antibody is capable of reducing the ability of human **Leukemia** Inhibitory Factor to induce release of intracellular calcium from **Jurkat** human T-cells, wherein the monoclonal antibody is competitively inhibited in its binding to human **Leukemia** Inhibitory Factor by a monoclonal antibody selected from the group consisting of monoclonal antibodies produced...

...A composition according to claim 1, wherein the monoclonal antibody has an affinity for human **Leukemia** Inhibitory Factor of at least 10⁹ liters/mole...

3/3,K,AB/4

DIALOG(R) File 340:CLAIMS(R)/US PATENT

(c) 2000 IFI/CLAIMS(r). All rts. reserv.

Dialog Acc No: 3072560 IFI Acc No: 9839091

Document Type: C

COMPOSITIONS AND METHODS FOR DETERMINING ANTI-VIRAL DRUG SUSCEPTIBILITY AND RESISTANCE AND ANTI-VIRAL DRUG SCREENING; MEASUREMENT, CALIBRATION GENE EXPRESSION

Inventors: Capon Daniel (US); Petropoulos Christos J (US)

Assignee: ViroLogic Inc Assignee Code: 47675

Patent (No,Date), Applic (No,Date)

US 5837464 19981117 US 97790963 19970129

Calculated Expiration: 20170129

Priority Applic(No,Date): US 97790963 19970129

Provisional Applic(No,Date): US 60-10715 19960129

Abstract:

This invention provides a method for determining susceptibility for an

anti-viral drug comprising: (a) introducing a resistance test vector comprising a patient-derived segment and an indicator gene into a host cell; (b) culturing the host cell from (a); (c) measuring expression of the indicator gene in a target host cell; and (d) comparing the expression of the indicator gene from (c) with the expression of the indicator gene measured when steps (a)-(c) are carried out in the absence of the anti-viral drug, wherein a test concentration of the anti-viral drug is present at steps (a)-(c); at steps (b)-(c); or at step (c). This invention also provides a method for determining anti-viral drug resistance in a patient comprising: (a) determining anti-viral drug susceptibility in the patient at a first time using the susceptibility test described above, wherein the patient-derived segment is obtained from the patient at about said time; (b) determining anti-viral drug susceptibility of the same patient at a later time; and (c) comparing the anti-viral drug susceptibilities determined in step (a) and (b), wherein a decrease in anti-viral drug susceptibility at the later time compared to the first time indicates development or progression of anti-viral drug resistance in the patient. This invention also provides a method for evaluating the biological effectiveness of a candidate anti-viral drug compound. Compositions including resistance test vectors comprising a patient-derived segment and an indicator gene and host cells transformed with the resistance test vectors are provided.

Non-exemplary Claims:

...The method of claim 1, wherein the target host cell is a human T cell leukemia cell line...

...25. The method of claim 1, wherein the target host cell is a Jurkat cell line...

3/3,K,AB/5

DIALOG(R) File 340:CLAIMS(R)/US PATENT

(c) 2000 IFI/CLAIMS(r). All rts. reserv.

Dialog Acc No: 2884504 IFI Acc No: 9726056

Document Type: C

NUCLEIC ACID ENCODING MONOCLONAL ANTIBODIES TO **LEUKEMIA** INHIBITORY FACTOR

Inventors: Kim Kyung Jin (US)

Assignee: Genentech Inc Assignee Code: 07579

Patent (No,Date), Applic (No,Date)

US 5668003 19970916 US 95438455 19950510

Calculated Expiration: 20140916

Continuation Pat(No),Applic(No,Date): ABANDONED US 92880400

19920508; ABANDONED US 9356966 19930429

Division Pat(No),Applic(No,Date): US 94258918
19940613

Priority Applic(No,Date): US 95438455 19950510; US 92880400 19920508;

US 9356966 19930429; US 94258918 19940613

Abstract:

The invention relates to nucleic acids encoding monoclonal antibodies to human leukemia inhibitory factor. The disclosed monoclonal antibodies are believed to recognize unique epitopes on hLIF and are useful in the treatment of conditions wherein the presence of hLIF causes or contributes to undesirable pathological effects, such as cachexia, dysregulated calcium metabolism, or excessive bone cell proliferation, and in the detection of hLIF, for example, in clinical samples or specimens.

NUCLEIC ACID ENCODING MONOCLONAL ANTIBODIES TO **LEUKEMIA** INHIBITORY FACTOR

Abstract:

The invention relates to nucleic acids encoding monoclonal antibodies to human **leukemia** inhibitory factor. The disclosed monoclonal antibodies are believed to recognize unique epitopes on hLIF and...

Exemplary Claim:

...R A W I N G

1. An isolated nucleic acid encoding an anti-human **Leukemia** Inhibitory Factor monoclonal antibody capable of being competitively inhibited in its binding to human **Leukemia** Inhibitory Factor by a monoclonal antibody selected from the group consisting of mAb D3.14...

Non-exemplary Claims:

...of claim 1, wherein the encoded antibody is capable of reducing the ability of human **Leukemia** Inhibitory Factor to inhibit growth of M1-T22 murine myeloid leukemic cells...

...of claim 1, wherein the encoded antibody is capable of reducing the ability of human **Leukemia** Inhibitory Factor to induce release of intracellular calcium from **Jurkat** human T-cells, and wherein the antibody is competitively inhibited in its binding to human **Leukemia** Inhibitory Factor by a monoclonal antibody selected from the group consisting of mAb D4.16...

...isolated nucleic acid of claim 1, wherein the encoded antibody has an affinity for human **Leukemia** Inhibitory Factor of at least 10⁹ liters/mole...

3/3,K,AB/6

DIALOG(R) File 340:CLAIMS(R)/US PATENT

(c) 2000 IFI/CLAIMS(r). All rts. reserv.

Dialog Acc No: 2868778 IFI Acc No: 9721268

Document Type: C

MONOCLONAL ANTIBODIES TO **LEUKEMIA** INHIBITORY FACTOR AND THEIR USE IN IMMUNOASSAYS; GENETIC ENGINEERING

Inventors: Kim Kyung Jin (US)

Assignee: Genentech Inc Assignee Code: 07579

Patent (No,Date), Applic (No,Date)

US 5654157 19970805 US 95438300 19950510

Calculated Expiration: 20140805

Document Type: CERTIFICATE OF CORRECTION Certificate of Correction Date: 19980623

Continuation Pat(No), Applic(No,Date): ABANDONED US 92880400
19920508; ABANDONED US 9356966 19930429

Division Pat(No), Applic(No,Date): US 94258918
19940613

Priority Applic(No,Date): US 95438300 19950510; US 92880400 19920508;
US 9356966 19930429; US 94258918 19940613

Abstract:

The invention relates to immunoassays utilizing monoclonal antibodies to human **leukemia** inhibitory factor. The disclosed monoclonal antibodies are believed to recognize unique epitopes on hLIF and are useful in the treatment of conditions wherein the presence of hLIF causes or contributes to undesirable pathological effects, such as cachexia, dysregulated calcium metabolism, or excessive bone cell proliferation, and in the detection of hLIF, for example, in clinical samples or specimens.

MONOCLONAL ANTIBODIES TO **LEUKEMIA** INHIBITORY FACTOR AND THEIR USE IN IMMUNOASSAYS...

Abstract:

The invention relates to immunoassays utilizing monoclonal antibodies to human **leukemia** inhibitory factor. The disclosed monoclonal antibodies

are believed to recognize unique epitopes on hLIF and...

Exemplary Claim:

...sample with a monoclonal antibody capable of being competitively inhibited in its binding to human **Leukemia** Inhibitory Factor by a monoclonal antibody selected from the group consisting of mAb D3.14...

...Collection Accession Numbers ATCC HB 11075, respectively) factor and (b) determining the amount of human **Leukemia** Inhibitory Factor in the test sample that is bound to the monoclonal antibody.

2. A monoclonal antibody capable of being competitively inhibited in its binding to human **Leukemia** Inhibitory Factor by a monoclonal antibody selected from the group consisting of mAb D3.14...

Non-exemplary Claims:

...immunoassay of claim 1, wherein the antibody is capable of reducing the ability of human **Leukemia** Inhibitory Factor to inhibit growth of M1-T22 murine myeloid leukemic cells...

...immunoassay of claim 1, wherein the antibody is capable of reducing the ability of human **Leukemia** Inhibitory Factor to induce release of intracellular calcium from **Jurkat** human T-cells, and wherein the antibody is competitively inhibited in its binding to human **Leukemia** Inhibitory Factor by a monoclonal antibody selected from the group consisting of mAb D4.16...

...5. The immunoassay of claim 1, wherein the antibody has an affinity for human **Leukemia** Inhibitory Factor of at least 10⁹ liters/mole...

...antibody of claim 2, wherein the antibody is capable of reducing the ability of human **Leukemia** Inhibitory Factor to inhibit growth of M1-T22 murine myeloid leukemic cells...

...antibody of claim 2, wherein the antibody is capable of reducing the ability of human **Leukemia** Inhibitory Factor to induce release of intracellular calcium from **Jurkat** human T-cells, and wherein the antibody is competitively inhibited in its binding to human **Leukemia** Inhibitory Factor by a monoclonal antibody selected from the group consisting of mAb D4.16...

...16. The antibody of claim 2, wherein the antibody has an affinity for human **Leukemia** Inhibitory Factor of at least 10⁹ liters/mole...

3/3,K,AB/7

DIALOG(R)File 340:CLAIMS(R)/US PATENT

(c) 2000 IFI/CLAIMS(r). All rts. reserv.

Dialog Acc No: 2854382 IFI Acc No: 9717032

Document Type: C

PROTEIN PRODUCTION AND PROTEIN DELIVERY; NEW TRANSCRIPTION UNIT COMPRISES EXOGENOUS REGULATORY SEQUENCE,EXOGENOUS EXON AND SPLICE-DONOR SITE, OPERATIVELY LINKED TO SECOND EXON OF ENDOGENOUS GENE

Inventors: Heartlein Michael W (US); Selden Richard F (US); Treco Douglas A (US)

Assignee: Transkaryotic Therapies Inc Assignee Code: 40420

Patent (No,Date), Applic (No,Date)

US 5641670 19970624 US 94243391 19940513

Calculated Expiration: 20140624

Document Type: CERTIFICATE OF CORRECTION Certificate of Correction Date: 19971028

Cont.-in-part Pat(No),Applic(No,Date): ABANDONED US 91787840

19911105; ABANDONED US 91789188 19911105; ABANDONED

US 92911533 19920710; ABANDONED US 92985586

19921203

Priority Applic(No,Date): US 94243391 19940513; US 91787840 19911105;

US 91789188 19911105; US 92911533 19920710; US 92985586 19921203

Abstract:

- The invention relates to constructs comprising: a) a targeting sequence; b) a regulatory sequence; c) an exon; and d) an unpaired splice-donor site. The invention further relates to a method of producing protein in vitro or in vivo comprising the homologous recombination of a construct as described above within a cell. The homologously recombinant cell is then maintained under conditions which will permit transcription and translation, resulting in protein expression. The present invention further relates to homologously recombinant cells, including primary, secondary, or immortalized vertebrate cells, methods of making the cells, methods of homologous recombination to produce fusion genes, methods of altering gene expression in the cells, and methods of making a protein in a cell employing the constructs of the invention.

Non-exemplary Claims:

...HT1080 cells, HeLa cells, derivatives of HeLa cells, MCF-7 breast cancer cells, K-562 leukemia cells, KB carcinoma cells, 2780AD ovarian carcinoma cells, Raji cells, Jurkat cells, Namalwa cells, HL-60 cells, Daudi cells, RPMI 8226 cells, U-937 cells, Bowes...

3/3,K,AB/8

DIALOG(R)File 340:CLAIMS(R)/US PATENT

(c) 2000 IFI/CLAIMS(r). All rts. reserv.

Dialog Acc No: 2072905 IFI Acc No: 9018408

Document Type: C

PROCESS FOR MAKING T CELL HYBRIDOMAS; FUSING AZASERINE-HYPOXANTHINE SENSITIVE HUMAN T LEUKEMIA CELL WITH NORMAL T CELLS, CULTURING

Inventors: Engleman Edgar G (US); Fount Steven K (US); Larrick James W (US); Raubitschek Andrew A (US)

Assignee: Cetus Corp; Stanford, Leland Jr University Trustees

Assignee Code: 15428 49136 Document Type: REASSIGNED

Patent (No,Date), Applic (No,Date)

~~US 4950598 19900821 US 85777947 19850919~~

Calculated Expiration: 20070821

Document Type: EXPIRED

Continuation Pat(No),Applic(No,Date): ABANDONED
19820922

US 82421060

Cont.-in-part Pat(No),Applic(No,Date): ABANDONED
19820507

US 82376191

Priority Applic(No,Date): US 85777947 19850919; US 82421060 19820922;
US 82376191 19820507

Abstract:

Human T-T hybridomas are made by fusing an azaserinehypoxanthine (AH) sensitive T leukemia cell line, preferably the AH-sensitive mutant of the Jurkat leukemia line identified as J3R7, with normal T cells and culturing the fusion product in a selective AH medium. Stable, interleukin-2 (IL-2)-producing human T-T hybridomas were made by this process.

...FUSING AZASERINE-HYPOXANTHINE SENSITIVE HUMAN T LEUKEMIA CELL WITH NORMAL T CELLS, CULTURING

Abstract:

Human T-T hybridomas are made by fusing an azaserinehypoxanthine (AH) sensitive T leukemia cell line, preferably the AH-sensitive mutant of the Jurkat leukemia line identified as J3R7, with normal T cells and culturing the fusion product in a...

Exemplary Claim:

...for making a T cell hybridoma comprising: a. Fusing an

azaserine-hypoxanthine sensitive human T leukemia cell line with normal human T cells; and b. culturing the product of step a. in a selective azaserinehypoxanthine medium, wherein said human T leukemia cell line is a derived from the Jurkat human T cell line.

Non-exemplary Claims:

- ...claim 1 wherein the T cell hybridoma is a human T cell hybridoma, the T leukemia cell line is a human T leukemia line and the normal T cells are normal human T cells...
- ...5. The process of claim 4 wherein the azaserine-hypoxanthine sensitive human T leukemia line has the identifying characteristics of the human T leukemia cell line ATCC number CRL 8169...
- ...6. The process of claim 4 wherein the azaserine-hypoxanthine sensitive human T leukemia line is the J3R7 cell line...
- ...9. The process of claim 8 wherein the azaserine-hypoxanthine sensitive T leukemia cell line has the identifying characteristics of ATCC number CRL 8169...
- ...10. The process of claim 8 wherein the azaserine-hypoxanthine sensitive T leukemia cells are cells of the Jurkat cell line...
- ...11. An azaserine-hypoxanthine sensitive mutant of the Jurkat human T leukemia cell line and progeny thereof...
- ...12. A human T leukemia cell line having all the identifying characteristics of ATCC number CRL 8169 and progeny thereof...
- ...13. Jurkat human T leukemia cell line J3R7 and progeny thereof...
- ...culturing a hybridoma produced by the fusion of an azaserine-hypoxanthine sensitive human T cell leukemia cell line and a normal human T cell, wherein said human T leukemia cell line is derived from the Jurkat human T cell line, and wherein the cloning is carried out in the presence of...

3/3,K,AB/9

DIALOG(R)File 340:CLAIMS(R)/US PATENT
(c) 2000 IFI/CLAIMS(r). All rts. reserv.

Dialog Acc No: 1471504 IFI Acc No: 8312179
Document Type: C
PROCESS FOR PREPARING HUMAN INTERLEUKIN 2; FROM MALIGNANT CELL CULTURE
Inventors: GILLIS STEVEN (US)
Assignee: IMMUNEX CORP Assignee Code: 09809
Patent (No,Date), Applic (No,Date)
US 4401756 19830830 US 81249905 19810414
Calculated Expiration: 20010414
(Cited in 034 later patents) Document Type: EXPIRED Document Type:
CERTIFICATE OF CORRECTION Certificate of Correction Date: 19840417
Priority Applic(No,Date): US 81249905 19810414

Abstract:

A process for preparing IL-2 from human malignant cells includes culturing human leukemia or lymphoma cells in vitro in a serum containing medium supplemented with various additives. The culture is stimulated by an optimum concentration of a T cell mitogen to produce a supernate which contains IL-2. After a period of time, the supernate is collected and processed to purify the IL-2. Phorbol myristate acetate may be added to the culture medium to boost production of IL-2.

Abstract:

A process for preparing IL-2 from human malignant cells includes culturing

human leukemia or lymphoma cells in vitro in a serum containing medium supplemented with various additives. The...

Non-exemplary Claims:

...3. The process of claim 2, wherein said T leukemic cells are Jurkat-FHCRC leukemic human T-cells...